Probi AB is a Swedish pharmaceutical company with a focus on probiotic research and development. They specialize in manufacturing and selling well-documented probiotics with scientific health benefits, particularly in areas such as gut health, immune system support, and nutrient absorption. Probi AB operates in the Consumer Healthcare (CHC) and Functional Food (FF) sectors in regions including the United States, Sweden, EMEA (Europe, Middle East, and Africa), and APAC (Asia and the Pacific). With a medium ESG risk rating score of 24.7, Probi AB is committed to sustainability and governance in its operations.